Irofulven, a novel inhibitor of DNA synthesis, in metastatic renal cell cancer

Robert J. Amato, Cherie Perez, Lance Pagliaro

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Irofulven (6-Hydroxymethylacylfulvene, MGI-114) is the first of a new class of anticancer compounds the acylfulvenes which are derived from the natural product, illudin S. Irofulven is a potent anticancer agent with activity against a broad range of human tumors in vitro and in vivo. Irofulven covalently binds to DNA, inhibits DNA synthesis and induces apoptosis. Clinical activity has been observed in phase I studies. Because disease stabilizations were observed in kidney cancer patients in the phase I trials, we performed a phase II trial of irofulven in this patient population. Twenty patients were accrued. Irofulven (11 milligrams per meter squared per day) was administered as a 5 minute intravenous infusion for 5 consecutive days, and response was evaluated every 8 weeks. There were no objective responses. The most common toxicities were nausea, emesis, and thrombocytopenia. Irofulven, at the dose and schedule administered in this trial, showed no effect in metastatic renal cell cancer.

Original languageEnglish (US)
Pages (from-to)413-417
Number of pages5
JournalInvestigational New Drugs
Volume20
Issue number4
DOIs
StatePublished - Nov 2002
Externally publishedYes

Fingerprint

Nucleic Acid Synthesis Inhibitors
Renal Cell Carcinoma
irofulven
Kidney Neoplasms
DNA
Biological Products
Intravenous Infusions
Thrombocytopenia
Antineoplastic Agents
Nausea
Vomiting
Appointments and Schedules
Apoptosis

Keywords

  • Irofulven
  • Kidney cancer
  • Phase II
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Irofulven, a novel inhibitor of DNA synthesis, in metastatic renal cell cancer. / Amato, Robert J.; Perez, Cherie; Pagliaro, Lance.

In: Investigational New Drugs, Vol. 20, No. 4, 11.2002, p. 413-417.

Research output: Contribution to journalArticle

Amato, Robert J. ; Perez, Cherie ; Pagliaro, Lance. / Irofulven, a novel inhibitor of DNA synthesis, in metastatic renal cell cancer. In: Investigational New Drugs. 2002 ; Vol. 20, No. 4. pp. 413-417.
@article{754685d78b3e426ca247ef51ad2d1662,
title = "Irofulven, a novel inhibitor of DNA synthesis, in metastatic renal cell cancer",
abstract = "Irofulven (6-Hydroxymethylacylfulvene, MGI-114) is the first of a new class of anticancer compounds the acylfulvenes which are derived from the natural product, illudin S. Irofulven is a potent anticancer agent with activity against a broad range of human tumors in vitro and in vivo. Irofulven covalently binds to DNA, inhibits DNA synthesis and induces apoptosis. Clinical activity has been observed in phase I studies. Because disease stabilizations were observed in kidney cancer patients in the phase I trials, we performed a phase II trial of irofulven in this patient population. Twenty patients were accrued. Irofulven (11 milligrams per meter squared per day) was administered as a 5 minute intravenous infusion for 5 consecutive days, and response was evaluated every 8 weeks. There were no objective responses. The most common toxicities were nausea, emesis, and thrombocytopenia. Irofulven, at the dose and schedule administered in this trial, showed no effect in metastatic renal cell cancer.",
keywords = "Irofulven, Kidney cancer, Phase II, Renal cell carcinoma",
author = "Amato, {Robert J.} and Cherie Perez and Lance Pagliaro",
year = "2002",
month = "11",
doi = "10.1023/A:1020649827173",
language = "English (US)",
volume = "20",
pages = "413--417",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "4",

}

TY - JOUR

T1 - Irofulven, a novel inhibitor of DNA synthesis, in metastatic renal cell cancer

AU - Amato, Robert J.

AU - Perez, Cherie

AU - Pagliaro, Lance

PY - 2002/11

Y1 - 2002/11

N2 - Irofulven (6-Hydroxymethylacylfulvene, MGI-114) is the first of a new class of anticancer compounds the acylfulvenes which are derived from the natural product, illudin S. Irofulven is a potent anticancer agent with activity against a broad range of human tumors in vitro and in vivo. Irofulven covalently binds to DNA, inhibits DNA synthesis and induces apoptosis. Clinical activity has been observed in phase I studies. Because disease stabilizations were observed in kidney cancer patients in the phase I trials, we performed a phase II trial of irofulven in this patient population. Twenty patients were accrued. Irofulven (11 milligrams per meter squared per day) was administered as a 5 minute intravenous infusion for 5 consecutive days, and response was evaluated every 8 weeks. There were no objective responses. The most common toxicities were nausea, emesis, and thrombocytopenia. Irofulven, at the dose and schedule administered in this trial, showed no effect in metastatic renal cell cancer.

AB - Irofulven (6-Hydroxymethylacylfulvene, MGI-114) is the first of a new class of anticancer compounds the acylfulvenes which are derived from the natural product, illudin S. Irofulven is a potent anticancer agent with activity against a broad range of human tumors in vitro and in vivo. Irofulven covalently binds to DNA, inhibits DNA synthesis and induces apoptosis. Clinical activity has been observed in phase I studies. Because disease stabilizations were observed in kidney cancer patients in the phase I trials, we performed a phase II trial of irofulven in this patient population. Twenty patients were accrued. Irofulven (11 milligrams per meter squared per day) was administered as a 5 minute intravenous infusion for 5 consecutive days, and response was evaluated every 8 weeks. There were no objective responses. The most common toxicities were nausea, emesis, and thrombocytopenia. Irofulven, at the dose and schedule administered in this trial, showed no effect in metastatic renal cell cancer.

KW - Irofulven

KW - Kidney cancer

KW - Phase II

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0036830077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036830077&partnerID=8YFLogxK

U2 - 10.1023/A:1020649827173

DO - 10.1023/A:1020649827173

M3 - Article

C2 - 12448659

AN - SCOPUS:0036830077

VL - 20

SP - 413

EP - 417

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 4

ER -